Navigation Links
Traumatic brain injury: NIH-funded researchers will assess biomarkers for diagnosis and treatment
Date:8/3/2011

Biomarkers in the bloodstream could provide physicians with a quick and accurate method of assessing the severity of traumatic brain injury (TBI) and helping deliver and monitor the results of therapies, such as progesterone treatment.

Researchers at Emory University School of Medicine, using a new $2.2 million, five-year grant from the National Institutes of Health, will study biomarkers in the blood of TBI patients, working with colleagues at the Medical University of South Carolina, the University of Pittsburgh, the University of Michigan and Banyan Biomarkers, Inc. The patients will already be enrolled in the NIH-funded Phase III clinical trial called ProTECT III (Progesterone for Traumatic brain injury, Experimental Clinical Treatment), assessing the use of progesterone to treat TBI in 1,140 patients at 17 centers nationwide.

"Rapid clinical assessment of the severity of traumatic brain injury (TBI) is a critical factor in diagnosis, treatment and prognosis. Yet current methods of assessment are inadequate and often inaccurate and there is a tremendous need for improvement," says Michael Frankel, MD, professor of neurology at Emory School of Medicine, Director of Grady Hospital's Marcus Stroke & Neuroscience Center, and principal investigator of the NIH-sponsored biomarker grant.

According to the Centers for Disease Control and Prevention, approximately 1.4 million Americans sustain a traumatic brain injury (TBI) each year, leading to 275,000 hospitalizations, 80,000 disabilities, and 52,000 deaths. In the Iraq/Afghanistan conflicts, approximately 20 percent of combat personnel suffer TBI.

Acute TBI leads to a cascade of cellular events set in motion by the initial injury that ultimately lead to cerebral edema (swelling of the brain), cellular disruption and sometimes death. Tissue breakdown leads to the release of proteins into the bloodstream. Several studies have shown that blood biomarkers correlate with outcome after TBI. Although preliminary studies suggest that serum levels of four biomarkers may more accurately predict the extent of injury than the commonly used Glasgow Coma Scale and CT scan, these have not yet been established as a reliable clinical tool.

Using the large patient group in the ProTECT III trial, the researchers hope to validate promising TBI biomarkers as predictors of clinical outcome and also evaluate the relationship between progesterone treatment, biomarker levels and outcome.

In an earlier pilot clinical trial several years ago, Emory researchers concluded that giving progesterone to trauma victims shortly following brain injury is safe and may reduce the risk of death and long-term disability. This led to the multicenter Phase III ProTECT trial currently underway.

"This new biomarker study should allow us to refine risk assessment for patients with moderate and severe TBI and evaluate the relationships between progesterone levels, serum biomarkers of structural injury in the brain, and clinical outcome," says Frankel. "This will not only help us assess the effectiveness of using progesterone to treat TBI, but will lead us to a more tailored approach for treatment of these patients."

Frankel also has been working as the principal investigator of another NIH-funded study in the innovative field of biomarkers, gathering data from the blood of stroke patients to determine who is at highest risk for recurrent stroke.


'/>"/>

Contact: Holly Korschun
hkorsch@emory.edu
404-727-3990
Emory University
Source:Eurekalert

Related medicine news :

1. Scott & White Memorial Hospital uses device to revolutionize treatment of traumatic aortic injury
2. Traumatic Amputations in Children Have High Costs
3. Research team documents benefits of endovascular stent repair for traumatic aortic injury
4. Survivors of childhood cancers 4 times more likely to develop post-traumatic stress disorder
5. UCLA researchers, US military collaborate to open center for traumatic brain injury
6. Researchers urge reclassification of traumatic brain injury as chronic disease
7. National study finds 70 percent increase in basketball-related traumatic brain injuries
8. Researchers at SUNY Downstate find drug combination may treat traumatic brain injury
9. After traumatic event, early intervention reduces odds of PTSD in children by 73 percent
10. U of M researchers identify possible key to treating, understanding post-traumatic stress disorder
11. Researchers identify PTSD measures for use in traumatic brain injury research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... Wethersfield, Conn. (PRWEB) , ... March 28, 2017 ... ... company based in Wethersfield, Conn., has relocated its corporate headquarters to a new, ... and clients. , In October 2016, Qualidigm purchased a distressed office building ...
(Date:3/28/2017)... ... March 28, 2017 , ... With less than 10,000 dermatologists in the ... care can be limited while the desire to conquer breakouts and eliminate skincare stress ... for every customer online, today released its inaugural survey on the State of Acne ...
(Date:3/28/2017)... ... March 28, 2017 , ... In ... Self-Funding Success website has recently developed and published an informational resource that addresses ... created based on common inquiries the site’s team of third party administrator (TPA) ...
(Date:3/28/2017)... Ohio (PRWEB) , ... March 28, 2017 , ... Columbus ... was selected as one of few medical professionals in the country to sit on ... Founder of Juvly Aesthetics, in just 2 years Dr. Harper helped propel the clinic ...
(Date:3/28/2017)... , ... March 28, 2017 , ... ... be offered by the American Association of Integrative Medicine and available for application ... providers at the AutismOne 2017 Conference in Colorado Springs. , Ed Arranga, president ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... 2017 The National University of Singapore ... analytics company, signed a Memorandum of Understanding (MOU) ... in the region. Under this ... and Technology (BIGHEART) at NUS and Holmusk will ... to healthcare IT and medical device development. These ...
(Date:3/27/2017)... 27, 2017  ImMAGE Biotherapeutics (OTCMKTS: IMMG), an early-stage ... early toxicology and efficacy studies. The company is harnessing ... specific protein, MAGE A, in an effort to find ... After 4 weeks of treatment in transgenic ... little toxicity in a full toxicology report of various ...
(Date:3/27/2017)... Calif. , March 27, 2017  Sanderling ... acquired by Ethicon, a division of Johnson & ... System for the treatment of gastro-esophageal reflux disease ... sphincter augmentation (MSA) technology and the procedure is ... centers. Torax Medical was founded by ...
Breaking Medicine Technology: